Clinical trials
Treating people with cancer in clinical trials
CellCentric is focused on developing inobrodib to transform cancer treatment outcomes for maximum benefit to patients. Inobrodib has a defined spectrum of potential applications due to its mechanism of action. Different cancer indications can be targeted by inobrodib as a monotherapy or in combination with existing standard of care drugs.
Inobrodib was the first orally available drug of its kind and the first inhibitor of p300/CBP to be evaluated in clinical trials. For hematological malignancy applications in particular, oral administration is a key advantage.
Current clinical trials
Inobrodib has been evaluated in an extensive international Phase I/IIa clinical campaign.
Current Studies
Inobrodib has transitioned from Phase I safety and pharmacokinetic evaluation as a monotherapy, and is currently being evaluated in expansion cohorts, as well as in new drug combinations. The hematological malignancy program (NCT04068597) is led by Prof Tim Somervaille of the Christie Hospital, Manchester and the solid tumour trial (NCT03568656) is led by Prof Johann de Bono at the Royal Marsden Hospital/Institute of Cancer Research, London.
Note for Patients
Potential suitability for enrolment in an inobrodib clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.
